Not on air · 2 of 3 networks checked
Recipharm
- recipharm.com
- SE
- 3,152 employees
Recipharm’s ads on LinkedIn, Meta and Google, recorded by adsrunning. Browse the latest here for free. Sign up free to see all 104. Watch Recipharm with Starter to get each new one in your feed.
Watchlist with Starter · $49/mo
| Network | Status | Live ads | Nov 2025LinkedIn activity · 52 weeksOct 2026 | Checked | Next step |
|---|---|---|---|---|---|
| None recorded | 0 | Checked 29 Oct 2026 | See all 104 ads → | ||
| Meta | Not checked | — | |||
| Recently | 48 | Ads on the Google Ads Transparency Center | Checked 8 Oct 2026 | Collect them with the API → |
Recipharm has no live LinkedIn ads. We recorded 48 Google ads on 8 Oct 2026.
Latest ads
- LINKEDIN · IMAGESince 14 Sept 2026
Our white paper on cell and virus banking explores how to establish robust starting materials for scalable, compliant oncolytic virus development and manufacturing. You will learn: • How to determine the right cell and virus bank strategy for your program • How to plan for long-term storage, scalability, and future supply • How to reduce development and manufacturing risk
- LINKEDIN · VIDEOSince 14 Sept 2026
Our white paper on cell and virus banking examines the foundations of successful oncolytic virus manufacturing, highlighting the key planning decisions that can accelerate development and reduce risk. You will learn: • How to determine the right cell and virus bank strategy for your program • How to plan for long-term storage, scalability, and future supply • How to reduce development and manufacturing risk
- LINKEDIN · VIDEOSince 14 Sept 2026
Our latest white paper explores how next-generation upstream manufacturing strategies can unlock more efficient, scalable rAAV production for gene therapy programs. You will learn: • How to increase rAAV yields and full capsid rates through optimized upstream processing • How to scale successfully from process development through pilot-scale production • How to accelerate development timelines with a robust, platform-based approach
- LINKEDIN · IMAGESince 14 Sept 2026
Our latest case study shows how to overcome oncolytic virus manufacturing challenges to reach first-in-human clincal trials on an accelerated timeline. You will learn: • How to optimize and scale adenovirus manufacturing for clinical readiness • How to increase product titers while maintaining quality • How to manage tech transfer and scale-up with confidence
- LINKEDIN · VIDEOSince 14 Sept 2026
Our latest case study shows how to overcome oncolytic virus manufacturing challenges to reach first-in-human clincal trials on an accelerated timeline. You will learn: • How to optimize and scale adenovirus manufacturing for clinical readiness • How to increase product titers while maintaining quality • How to manage tech transfer and scale-up with confidence
- LINKEDIN · IMAGESince 14 Sept 2026
Our latest white paper explores how next-generation upstream manufacturing strategies can unlock more efficient, scalable rAAV production for gene therapy programs. You will learn: • How to increase rAAV yields and full capsid rates through optimized upstream processing • How to scale successfully from process development through pilot-scale production • How to accelerate development timelines with a robust, platform-based approach
6 of 104 adsSign up to see every Recipharm ad, filter by format and date, and get alerts on new ones.
See all 104 adsWatch the companies you care about.
Filter every ad by industry, country, format and network, and get alerts when a company you watch starts running new ads.